Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

In one aspect, the present disclosure relates to compounds which inhibit one or more -lactamases and/or penicillin binding proteins (PBPs), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating a bacterial infection in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of the present disclosure and/or at least one pharmaceutical composition of the present disclosure. In certain embodiments, the -lactamase is selected from the group consisting of NDM-1, KPC-2, and OXA-48. In certain embodiments, the PBP is PBP-3.

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

A betaine type iodonium salt containing a C6-C18 alkyl or C4-C18 fluorinated alkyl group and having a iodonium cation and a carboxylate anion within a common molecule is a useful quencher. A chemically amplified positive resist composition comprising the iodonium salt exhibits improved lithography properties such as resolution, LER and pattern profile when processed by photolithography.

A resist composition including a base material component whose solubility in a developing solution is changed by an action of an acid and a compound represented by General Formula (d0). In Formula (d0), Rf represents a fluorinated hydrocarbon group; V.sup.0 represents a hydrocarbon group which may have a substituent or a single bond; Y.sup.0 represents a divalent linking group having an oxygen atom; I represents an iodine atom; x represents an integer of 1 to 4, y represents an integer of 1 to 4; 2x+y5 is satisfied; a total number of fluorine atoms contained in x pieces of Rf's is 5 or more; M.sup.m+ represents a sulfonium cation or an iodonium cation; and m represents an integer of 1 or greater.

##STR00001##

A resist composition including a base material component whose solubility in a developing solution is changed by an action of an acid and a compound represented by General Formula (d0). In Formula (d0), Rf represents a fluorinated hydrocarbon group; V.sup.0 represents a hydrocarbon group which may have a substituent or a single bond; Y.sup.0 represents a divalent linking group having an oxygen atom; I represents an iodine atom; x represents an integer of 1 to 4, y represents an integer of 1 to 4; 2x+y5 is satisfied; a total number of fluorine atoms contained in x pieces of Rf's is 5 or more; M.sup.m+ represents a sulfonium cation or an iodonium cation; and m represents an integer of 1 or greater.

##STR00001##

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.